AMENDMENT

Kindly amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

IN THE CLAIMS:

Kindly amend the claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, to read as follows:

1. (Currently Amended) A DNA vaccine comprising (i) a naked DNA plasmid containing and expressing *in vivo* a polynucleotide encoding an antigenic polypeptide, wherein the antigenic polypeptide comprises an antigen of equine rhinopheumonia virus; and (ii) at least one adjuvant comprising carbopol ~~which is a polymer of acrylic or methacrylic acid or a copolymers of maleic anhydride and alkenyl~~.

2. (Cancelled)

3. (Cancelled)

4. (Cancelled)

5. (Previously Presented) The vaccine according to Claim 1, wherein the adjuvant is present in the vaccine in an amount of 0.01% to 2% w/v.

6. (Previously Presented) The vaccine according to Claim 5 wherein the adjuvant is present in a concentration of 0.06 to 1% w/v.

7. (Cancelled)

8. (Cancelled)

9. (Cancelled)

10. (Currently Amended) A method of enhancing efficacy of a DNA plasmid vaccine which comprises a naked DNA containing and expressing *in vivo* a heterologous polynucleotide, wherein the heterologous polynucleotide is an immunogen of equine rhinopheumonia virus by adding to the DNA vaccine Carbopol ~~an adjuvant which is a polymer of acrylic or methacrylic acid or a copolymers of maleic anhydride and alkenyl~~.

11. (Cancelled)~~.~~

12. (Cancelled)

13. (Currently Amended) The vaccine of claim ~~6~~ 10, wherein the adjuvant compound has a concentration of

0.06 to 1% w/v.

14. (Cancelled) ~~÷~~

15. (Cancelled)

16. (Cancelled)

17. (Cancelled)

18. (Cancelled)

19. (Currently Amended) The vaccine of claim 1, wherein the naked DNA plasmid is in the circular plasmid form, wherein the plasmid additionally comprises an origin of replication, a promoter, and a transcription termination sequence.